VEGFR1/Flt-1 Antibody [Biotin]

• Reactivity: Mu
• Applications: WB, ELISA(Det)
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Biotin
• Concentration: LYOPH

VEGFR1/Flt-1 Antibody [Biotin] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant mouse VEGFR1/Flt-1
  Ser27-Glu759
  Accession # P35969
• Specificity: Detects mouse VEGFR1 in ELISAs and Western blots. In sandwich ELISAs, less than 7% cross-reactivity with recombinant human VEGFR1 is observed, 4% cross-reactivity with recombinant mouse (rm) VEGF 164 is observed, 1% cross-reactivity with recombinant rat VEGF 164 is observed, and 0.2% cross-reactivity with rmVEGFR2 and rmVEGFR3 is observed.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Gene: FLT1
• Purity Statement: Antigen Affinity-purified

Applications/Dilutions

• Dilutions:
  • ELISA Capture (Matched Antibody Pair) 0.2-0.8 ug/mL
  • ELISA Detection (Matched Antibody Pair) 0.1-0.4 ug/mL
  • ELISA Standard (Matched Pair)
  • Western Blot 0.1 ug/mL
• Application Notes: ELISA Capture: Mouse VEGF R1/Flt-1 Antibody (Catalog # AF471) ELISA Detection: Mouse VEGF R1/Flt-1 Biotinylated Antibody (Catalog # BAF471) Standard: Recombinant Mouse VEGF R1/Flt-1 Fc Chimera (Catalog # 471-F1)
• Readout System:
  • Streptavidin Native Protein NBP2-29367
  • Streptavidin Native Protein NBP2-29370
  • Streptavidin Native Protein NBP2-29371

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  12 months from date of receipt, -20 to -70 degreesC as supplied. 1 month, 2 to 8 degreesC under sterile conditions after reconstitution. 6 months, -20 to -70 degreesC under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.2 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for VEGFR1/Flt-1 Antibody [Biotin]

• EC 2.7.10
• EC 2.7.10.1
• FLT
• FLT1
• Flt-1
• Fms-like tyrosine kinase 1
• fms-related tyrosine kinase 1 (vascular endothelial growth factor/vascularpermeability factor receptor)
• FRT
• Tyrosine-protein kinase FRT
• Tyrosine-protein kinase receptor FLT
• vascular endothelial growth factor receptor 1
• Vascular permeability factor receptor
• VEGF R1
• VEGFR1
• VEGFR-1

Background

VEGFR1 is one of the five receptor tyrosine kinases (RTKs) (VEGFR1, KDR/Flk-1, Flt-4, Tie-1, and Tek/Tie-2) whose expression is almost exclusively restricted to the endothelial cells. Tie-1 and tek/tie-2 define a new class of RTKs containing two immunoglobulin-like domains, three EGF homology domains and three fibronectin type III domains in their extracellular regions. VEGFR1/Flt-1, VEGFR2/KDR/Flk-1, VEGFR3/Flt-4 are members of the class III subfamily of RTKs containing seven immunoglobulin-like repeats in their extracellular domains. All five RTKs are likely to play central roles in vasculogenesis and angiogenesis. Full length mouse VEGFR1 mRNA encodes a 1333 amino acid (aa) residue precursor with a predicted 22 aa residue signal peptide. Mature VEGFR1 is composed of a 737 aa residue extracellular domain, a 22 aa residue transmembrane domain and a 552 aa residue cytoplasmic domain. As a result of alternative splicing of the mRNA, a cDNA encoding a truncated form of VEGFR1, lacking the seventh immunoglobulin-like domain, the transmembrane and intracellular domains, has been cloned. The recombinant soluble VEGFR1/Fc chimera binds VEGF and PlGF with high affinity and is a potent VEGF antagonist.

1. He, Y. et al. (1999) Molecular Endocrinology 13:537.
2. Ferrara, N. and T. Davis-Smyth (1997) Endocrine Reviews 8:4.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for VEGFR1/Flt-1 Antibody (BAF471)(3)

Publications using BAF471

• Yang Kyung Cho, Hironori Uehara, Jason R. Young, Bonnie Archer, Xiaohui Zhang, Balamurali K. Ambati Vascular Endothelial Growth Factor Receptor 1 Morpholino Decreases Angiogenesis in a Murine Corneal Suture Model Investigative Opthalmology & Visual Science 2012-02-13 [PMID: 22199251]
• Shin JY, Yoon IH, Kim JS, Kim B, Park CG Vascular endothelial growth factor-induced chemotaxis and IL-10 from T cells. Cell. Immunol., 2009-02-26;256(1):72-8. 2009-02-26 [PMID: 19249018] (Flow Cytometry, Mouse)
• Cianfarani F, Zambruno G, Brogelli L, Sera F, Lacal PM, Pesce M, Capogrossi MC, Failla CM, Napolitano M, Odorisio T Placenta growth factor in diabetic wound healing: altered expression and therapeutic potential. Am. J. Pathol., 2006-10-01;169(4):1167-82. 2006-10-01 [PMID: 17003476] (ELISA Development, Mouse)

Bioinformatics

• Gene Symbol: FLT1
• Uniprot:
  • P35969()